sec filing
LX
NASDAQ · LXEO
Lexeo Therapeutics, Inc. Common Stock
Healthcare · Biotechnology
$4.13
Down-$0.08 (-1.90%)
Updated Sep 16, 2026, 10:38 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 715.64M
- P/E ratio
- -3.74
- Dividend yield
- 0.00%
- 52-week range
- $3.99 – $8.00
- Volume
- 888.4K
- Avg. volume
- 1.28M
Price performance
LXEO price history
1M range · 20 trading sessions · Daily adjusted prices
LXEO closed at $4.13 after 20 trading sessions, down 16.23% for the selected period.
- Last close
- $4.13
- Period change
- -16.23%
- Period low
- $4.13
- Period high
- $5.37
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $4.18 | $4.275 | $4.01 | $4.13 | 888.4K |
| Sep 14, 2026 | $4.31 | $4.36 | $4.18 | $4.21 | 1.26M |
| Sep 11, 2026 | $4.43 | $4.475 | $4.205 | $4.25 | 1.49M |
| Sep 10, 2026 | $4.43 | $4.44 | $4.31 | $4.36 | 420.87K |
| Sep 9, 2026 | $4.72 | $4.805 | $4.48 | $4.48 | 311.69K |
| Sep 8, 2026 | $4.82 | $4.87 | $4.66 | $4.76 | 357.81K |
| Sep 4, 2026 | $4.76 | $4.99 | $4.76 | $4.89 | 296.44K |
| Sep 3, 2026 | $4.80 | $4.92 | $4.67 | $4.84 | 313.34K |
| Sep 2, 2026 | $4.76 | $4.96 | $4.65 | $4.78 | 468.36K |
| Sep 1, 2026 | $4.70 | $4.77 | $4.5639 | $4.70 | 420.48K |
| Aug 31, 2026 | $4.82 | $4.82 | $4.62 | $4.76 | 472.04K |
| Aug 28, 2026 | $4.96 | $4.96 | $4.73 | $4.86 | 663.61K |
| Aug 27, 2026 | $4.97 | $5.09 | $4.885 | $4.99 | 1.11M |
| Aug 26, 2026 | $5.10 | $5.11 | $4.91 | $5.01 | 689.96K |
| Aug 25, 2026 | $4.97 | $5.13 | $4.94 | $5.13 | 937.38K |
| Aug 24, 2026 | $4.88 | $4.965 | $4.70 | $4.92 | 518.5K |
| Aug 21, 2026 | $5.12 | $5.204 | $4.84 | $4.88 | 509.59K |
| Aug 20, 2026 | $5.29 | $5.355 | $4.90 | $5.06 | 1.11M |
| Aug 19, 2026 | $5.07 | $5.405 | $5.05 | $5.37 | 941.95K |
| Aug 18, 2026 | $4.94 | $5.05 | $4.825 | $4.93 | 649.79K |
Latest LXEO news
The latest Smart Investors Daily articles mentioning LXEO.
Stock researchCompany · Overview
LXEO research
Overview
Company profile and research snapshot.
Company profile
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $19.83
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 25, 2026 | JP Morgan | Overweight | — |
| May 11, 2026 | Chardan Capital | Buy | — |
| Jan 13, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 13, 2026 | Chardan Capital | Buy | — |
| Dec 18, 2025 | Raymond James | Strong Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.